Tosatoxumab
Based on 1 Customer Validation
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.00%
- CAS 番号: 1374419-41-6
- 分子量:144.92 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
Human IgG1 lambda
Human
alpha toxin
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
3920722 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 1374419-41-6
-
性状 Liquid
-
分子量 144.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Tosatoxumab]
-
別名
KBSA301; AR-301
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Bruno François, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018 Nov;44(11):1787-1796. [Content Brief]
[2]. Philippe Vignon, et al. New Agents in Development for Sepsis: Any Reason for Hope? Drugs. 2020 Nov;80(17):1751-1761. [Content Brief]
[3]. Lugovskoy, A. A., et al., (2012). 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. mAbs, 4(2), 134–152. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)